![Autism And Cbd: What Science Says About Hemp Therapy [FItVIfuYe3z]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/09/ced-pexels-13091435.jpg?resize=150%2C150&ssl=1 "Autism And Cbd: What Science Says About Hemp Therapy [FItVIfuYe3z] 26")
In the Mix: 10 More Articles — March 19, 2026
This article reviews cannabis regulatory enforcement challenges 2026 impacting legal cannabis markets and clinical practice. It highlights key compliance issues and regulatory updates. Understanding these challenges is essential for clinicians and…
The Right Schedule for Marijuana Does Not Yet Exist
2026 cannabis schedule classification challenges create significant legal barriers that limit clinical research. These challenges hinder establishing evidence-based dosing and safety profiles. Until reforms align with science, clinicians face…
DEA Admits Teen Cannabis Use Has Drastically Decreased Since 1995, Despite Dozens of …
The DEA admits legal cannabis isn't increasing youth use, highlighting a significant decline in adolescent cannabis consumption since 1995. This challenges common assumptions about legalization and youth behavior. Clinicians can use this data to inform…
Georgia bill could limit probable cause for smell of marijuana, cannabis, or hemp – YouTube
The georgia bill probable cause cannabis odor limits law enforcement's ability to use cannabis smell as probable cause for vehicle searches. This reflects legal recognition that smell alone cannot distinguish marijuana from hemp. The bill impacts…
Czech Republic Decides to Ban HHC – Possession to Become Punishable in the Future
The Czech Republic HHC ban marks a significant shift in synthetic cannabinoid regulation. Possession of HHC will become punishable, impacting patient access and safety. Clinicians should stay informed about this evolving legal landscape.
Congressional Researchers Provide Update on Marijuana Rescheduling and Hemp Policy
Marijuana rescheduling federal research is under active congressional review, affecting clinical practice and research access. Current federal Schedule I status limits federally funded cannabis studies. Changes in rescheduling could enhance…
Feds Maintain Marijuana Testing Despite Cannabis Reclassification
Federal workplace drug testing policies continue to screen for marijuana metabolites despite cannabis reclassification. This creates challenges for patients using cannabis medicinally in safety-sensitive jobs. Clinicians should counsel patients on the…
As a Medical Cannabis Patient, I’m Watching This Supreme Court Case Closely
The supreme court medical cannabis case has significant implications for patient legal protections. This case could affect state medical cannabis programs and patient access. Clinicians and patients alike should monitor this evolving legal landscape…
In the Mix: 5 More Articles — March 15, 2026
This article reviews recent cannabis policy developments relevant to clinicians. It highlights regulatory disputes and labor safety issues in the cannabis industry. Understanding these developments is crucial for clinical frameworks addressing cannabis…
This Week in Cannabis: Clinical Research & Policy Highlights
This week in cannabis clinical research outcomes highlights key findings in therapeutic applications and policy developments. Regulatory scheduling changes continue to shape access and use. Stay informed on the latest cannabis clinical research outcomes…